Supreme Court Keeps Abortion Pill Available Through Thursday as Justices Weigh Restrictions

Justice Samuel Alito ordered Monday that women across the country may continue obtaining mifepristone at pharmacies or through the mail without an in-person doctor visit — at least until Thursday, when the Supreme Court is expected to act further on whether to let appellate restrictions on the widely used abortion pill take effect.

The temporary order blocks a ruling by a three-judge panel of the Fifth U.S. Circuit Court of Appeals, which had concluded that mail access and telehealth prescriptions for mifepristone should be suspended while a Louisiana lawsuit challenging Food and Drug Administration rules on the drug works its way through the courts. Louisiana argues the FDA's permissive prescribing rules undermine the state's abortion ban and raise unresolved safety questions about the drug. Lower courts found the state is likely to prevail on the merits.

For Treasure Coast residents in Martin, St. Lucie and Indian River counties, the stakes are concrete: mifepristone is dispensed at pharmacies under rules that allow any certified prescriber — not just a specialist — to authorize the drug through a telehealth visit. A ruling that suspends those rules would eliminate that access channel for women in the region, where in-person abortion providers are scarce.

Medication abortions — most often a two-drug regimen of mifepristone and misoprostol — accounted for nearly two-thirds of all abortions in the United States in 2023, the last year for which data are available, according to federal statistics. The FDA first approved mifepristone in 2000 and has repeatedly reviewed and deemed it safe and effective, according to agency scientists.

The case echoes a nearly identical legal fight three years ago, when a separate group of physicians who oppose abortion challenged mifepristone access. The Supreme Court blocked that Fifth Circuit ruling — over the dissenting votes of Alito and Justice Clarence Thomas — before unanimously dismissing the case in 2024 on the grounds that the plaintiffs lacked legal standing to sue.

This time, Louisiana's standing as a state may prove a stronger legal foundation. Mainstream medical organizations, the pharmaceutical industry and Democratic members of Congress have urged the court not to restrict the drug, with pharmaceutical companies warning that a ruling for abortion opponents could destabilize the broader FDA drug-approval process.

The Trump administration has not filed a written brief in the case, an unusual absence given that federal regulations are directly at issue. Both sides have interpreted the silence as tacit support for the appellate court's restrictions.

Alito, who authored the 2022 decision overturning Roe v. Wade, is the justice assigned to handle emergency appeals from Louisiana. The full court is expected to weigh in by Thursday.

This article was generated with AI assistance using publicly available information. It was reviewed and approved by a human editor before publication. TC Sentinel uses AI writing tools in accordance with FTC guidelines.